While pharmacological agonists of the GR (e.g., prednisone and dexamethasone) have been intensively used as therapeutics in the treatment of lymphoid cancers, for non-lymphoid solid (i.e., non-haematologic) cancer patients they are utilised solely as an adjuvant treatment to alleviate symptoms caused by anticancer therapy. The gene discussed is NR3C1; the disease is cancer.